- Home
- MBIN vs AMLX Comparison
MBIN vs AMLX Comparison
Compare MBIN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIN | AMLX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 735 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBIN | AMLX |
|---|---|---|
| Price | $54.87 | $19.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $43.67 | $21.56 |
| AVG Volume (30 Days) | 143.9K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $31.76 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $29.20 | $7.48 |
| 52 Week High | $56.87 | $20.90 |
Technical Indicators
Market Signals| Indicator | MBIN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 73.49 | 64.54 |
| Support Level | $45.39 | $12.14 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.76 | 1.23 |
| MACD | 0.79 | 0.17 |
| Stochastic Oscillator | 89.97 | 82.24 |
Price Performance
Historical ComparisonAbout MBIN Merchants Bancorp
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.